LONDON & SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) and Genomics England today announce a partnership to develop a platform and knowledge base that can be used to improve and automate genome interpretation. The tools will operate within the Genomics England secure database to enable researchers and clinicians to access information and reports more readily.
